McNeil, JJ and Wolfe, R and Woods, RL and Tonkin, AM and Donnan, GA and Nelson, MR and Reid, CM and Lockery, JE and Kirpach, B and Storey, E and Shah, RC and Williamson, JD and Margolis, KL and Ernst, ME and Abhayaratna, WP and Stocks, N and Fitzgerald, SM and Orchard, SG and Trevaks, RE and Beilin, LJ and Johnston, CI and Ryan, J and Radziszewska, B and Jelinek, M and Malik, M and Eaton, CB and Brauer, D and Cloud, G and Wood, EM and Mahady, SE and Satterfield, S and Grimm, R and Murray, AM, for the ASPREE Investigator Group, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, New England Journal of Medicine, 379, (16) pp. 1509-1518. ISSN 0028-4793 (2018) [Refereed Article]
Copyright 2018 Massachusetts Medical Society
Methods: From 2010 through 2014, we enrolled community-dwelling men and women in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or disability. Participants were randomly assigned to receive 100 mg of enteric-coated aspirin or placebo. The primary end point was a composite of death, dementia, or persistent physical disability; results for this end point are reported in another article in the Journal. Secondary end points included major hemorrhage and cardiovascular disease (defined as fatal coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal stroke, or hospitalization for heart failure).
Results: Of the 19,114 persons who were enrolled in the trial, 9525 were assigned to receive aspirin and 9589 to receive placebo. After a median of 4.7 years of follow-up, the rate of cardiovascular disease was 10.7 events per 1000 person-years in the aspirin group and 11.3 events per 1000 person-years in the placebo group (hazard ratio, 0.95; 95% confidence interval [CI], 0.83 to 1.08). The rate of major hemorrhage was 8.6 events per 1000 person-years and 6.2 events per 1000 person-years, respectively (hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P<0.001).
Conclusions: The use of low-dose aspirin as a primary prevention strategy in older adults resulted in a significantly higher risk of major hemorrhage and did not result in a significantly lower risk of cardiovascular disease than placebo.
|Item Type:||Refereed Article|
|Keywords:||aspirin, cardiovascular events, healthy elderly|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Cardiovascular medicine and haematology|
|Research Field:||Cardiology (incl. cardiovascular diseases)|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Nelson, MR (Professor Mark Nelson)|
|Web of Science® Times Cited:||378|
|Deposited By:||Menzies Institute for Medical Research|
|Downloads:||143 View Download Statistics|
Repository Staff Only: item control page